Diabetic Kidney Disease

Diabetic Kidney Disease (DKD) is the most frequent cause for end stage renal disease (ESRD). The UCLA DKD Program strives to accomplish by providing comprehensive patient care, educating the public about DKD, and performing research in order to advance the field and develop new medications. There is an increasing need for new therapeutic agents that effectively target underlying DKD mechanisms and slow the progression of kidney disease, as the type 2 diabetes mellitus population continues to grow rapidly throughout the world, and with it the DKD population.

Interventions to improve outcomes related to DKD focus on reducing risk via lifestyle modification counseling (i.e. smoking cessation and dietary modifications to reduce proteinuria and aid in weight loss) as well as interventions aimed at glycemic control, dyslipidemia, and hypertension.

The UCLA DKD program is committed to ongoing research, including basic science, applied clinical science, outcomes, and evidence-based research in the mission to develop new treatments and cures for Diabetic Kidney Disease.

Learn how you can support the UCLA DKD Program by visiting giving.ucla.edu/kidney.